Interdigitating dendritic cell sarcoma

Researchers are testing whether adding pirtobrutinib to methotrexate and standard chemoimmunotherapy can help people with diffuse large B-cell lymphoma that has spread to the central nervous system. The trial enrolls about 24 people aged 14 to 80 whose lymphoma involves the brain…

This early-phase trial tests a personalized cell therapy (rapcabtagene autoleucel) in 20 adults with large B-cell lymphoma who still have traces of cancer after initial treatment. The goal is to see if the therapy can make those traces disappear, potentially lowering the risk of …

This phase 2 trial is testing whether adding the targeted drug pirtobrutinib to a standard chemotherapy regimen (Pola-R-CHP) can improve outcomes for people newly diagnosed with a specific, harder-to-treat subtype of diffuse large B-cell lymphoma (Non-GCB DLBCL). The study will e…

This trial is testing whether adding pirtobrutinib, a targeted drug, to the standard R-CHOP chemotherapy regimen can improve outcomes for people with a specific subtype of diffuse large B-cell lymphoma (non-GCB DLBCL). The study will enroll about 34 adults with newly diagnosed di…

This phase II trial is testing whether a combination of two targeted drugs—pirtobrutinib and sonrotoclax—can shrink tumors in people with three types of B-cell lymphoma: transformed diffuse large B-cell lymphoma, relapsed or refractory chronic lymphocytic leukemia/small lymphocyt…

This phase 2 trial is testing the drug glofitamab in people with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL). Glofitamab is a type of immunotherapy that helps the body's T-cells attack cancer cells. The study uses tumor biopsies tak…

This phase 2 trial tests whether adding the targeted drug orelabrutinib to standard chemotherapy improves outcomes for people with a specific genetic subtype of diffuse large B-cell lymphoma (MCD subtype). Participants receive the drug combination during initial treatment, follow…

This phase 2 trial tests a combination of seven drugs (CL-Pola-R-CHP) in 28 adults aged 65 and older with double or triple-hit diffuse large B-cell lymphoma who are not eligible for transplant. The goal is to see how many patients achieve complete remission after six cycles of tr…

This study tests whether a new drug combination (C Pola R-CHP+X) works better than the standard treatment (CR-CHOP) for people with a fast-growing type of lymphoma called double-expressor diffuse large B-cell lymphoma. About 156 adults aged 18-75 who have not been treated before …

This study looks at how well the drug glofitamab works for people with a type of blood cancer called diffuse large B-cell lymphoma that did not respond to or came back after initial treatment. About 20 adults will take part, and their doctors will decide if they get glofitamab al…

This phase II trial will test two different drug combinations in 70 people whose diffuse large B-cell lymphoma has returned more than a year after initial treatment. One group gets a modified R-MINE regimen (rituximab, ifosfamide, mitoxantrone liposome, etoposide), the other gets…

This study tests whether combining two powerful treatments—glofitamab and CAR-T therapy—can help people with a high-risk, hard-to-treat type of large B-cell lymphoma that has come back or not responded to prior treatment. About 24 adults will receive the combination and be monito…

This Phase II trial is testing a combination of three drugs—glofitamab, polatuzumab vedotin, and zuberitamab—in 40 people newly diagnosed with diffuse large B-cell lymphoma. The goal is to see if this chemo-free approach can achieve complete remission early in treatment. Particip…